Annual report
7129.TEDINET S100OG2Y
Period2021-10-01 → 2022-03-31
Filed2022-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 38
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥19.5bn | 2021-10-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥186m | 2021-10-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥190m | 2021-10-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥534m | 2021-10-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥292m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥292m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥14.2bn | at 2022-03-31 | Cons. | Assets |
| Total liabilities | ¥11.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.0bn | at 2021-09-30 | Cons. | Net assets |
| Cash and deposits | ¥1.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥691m | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥919m | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.5bn | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥2.0bn | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥117.49 | 2021-10-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥116.61 | 2021-10-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,287.13 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 22.5% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.4% | 2021-10-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,752 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥116m | 2021-10-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Operating income | ¥52m | 2021-10-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥52m | 2021-10-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | ¥52m | 2021-10-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥62m | 2021-10-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥3.1bn | at 2022-03-31 | Standalone | Assets |
| Total liabilities | ¥71m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.1bn | at 2022-03-31 | Standalone | Net assets |
| Cash and deposits | ¥3m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥24.86 | 2021-10-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥24.68 | 2021-10-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥17 | 2021-10-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,232.94 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 97.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.0% | 2021-10-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 2,488,300 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-10-01 → 2022-03-31 | ¥237,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-10-01 → 2022-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 22 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-10-01 → 2022-03-31 | ¥932m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-10-01 → 2022-03-31 | ¥905m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥27m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥165m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-10-01 → 2022-03-31 | ¥39m |
| Reconciling Itemsreconciling | capex | 2021-10-01 → 2022-03-31 | ¥218m |
| Reconciling Itemsreconciling | depreciation | 2021-10-01 → 2022-03-31 | ¥42m |
| Reconciling Itemsreconciling | revenue | 2021-10-01 → 2022-03-31 | −¥27m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-10-01 → 2022-03-31 | −¥27m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-10-01 → 2022-03-31 | −¥798m |
| Medicine Businessreportable segment | capex | 2021-10-01 → 2022-03-31 | ¥175m |
| Medicine Businessreportable segment | depreciation | 2021-10-01 → 2022-03-31 | ¥68m |
| Medicine Businessreportable segment | employees | at 2022-03-31 | 194 pure |
| Medicine Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥8.8bn |
| Medicine Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥8.8bn |
| Medicine Businessreportable segment | segment assets | at 2022-03-31 | ¥2.9bn |
| Medicine Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥559m |
| Nursing Care Businessreportable segment | capex | 2021-10-01 → 2022-03-31 | ¥69m |
| Nursing Care Businessreportable segment | depreciation | 2021-10-01 → 2022-03-31 | ¥55m |
| Nursing Care Businessreportable segment | employees | at 2022-03-31 | 290 pure |
| Nursing Care Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥3.4bn |
| Nursing Care Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥3.4bn |
| Nursing Care Businessreportable segment | segment assets | at 2022-03-31 | ¥1.2bn |
| Nursing Care Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥25m |
| Nurturing Businessreportable segment | capex | 2021-10-01 → 2022-03-31 | ¥2.6bn |
| Nurturing Businessreportable segment | depreciation | 2021-10-01 → 2022-03-31 | ¥307m |
| Nurturing Businessreportable segment | employees | at 2022-03-31 | 1192 pure |
| Nurturing Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥6.4bn |
| Nurturing Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥6.4bn |
| Nurturing Businessreportable segment | segment assets | at 2022-03-31 | ¥7.8bn |
| Nurturing Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥362m |
| —segment total | capex | 2021-10-01 → 2022-03-31 | ¥2.9bn |
| —segment total | depreciation | 2021-10-01 → 2022-03-31 | ¥430m |
| —segment total | revenue | 2021-10-01 → 2022-03-31 | ¥18.6bn |
| —segment total | revenue external | 2021-10-01 → 2022-03-31 | ¥18.6bn |
| —segment total | segment assets | at 2022-03-31 | ¥12.0bn |
| —segment total | segment profit | 2021-10-01 → 2022-03-31 | ¥946m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-10-01 → 2022-03-31 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-10-01 → 2022-03-31 | ¥434m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-10-01 → 2022-03-31 | ¥19.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-10-01 → 2022-03-31 | ¥19.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥27m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥12.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-10-01 → 2022-03-31 | ¥985m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 794
| Item | Context | Value | Unit |
|---|---|---|---|
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000HaraMasaoMember | Original text (Japanese)取締役（監査等委員） | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000HaraMasaoMember | Original text (Japanese)原 正雄 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000HaraMasaoMember | 1973-11-30 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E36714-000HaraMasaoMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000HaraMasaoMember | Original text (Japanese)(注)４ | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row6Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row7Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Note on change of independent auditors audits (text) | CurrentYearDuration | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Name of group company holding largest amount of investment shares in group | CurrentYearInstant | Original text (Japanese)ライフサポート株式会社 | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Notes no description of the comparative information financial information (text) | CurrentYearDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Changes in scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes additional information consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding accumulated depreciation of property plant and equipment (text) | CurrentYearInstant | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding financial covenant clauses (text) | CurrentYearInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding loss on disposal of property plant and equipment (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding impairment loss (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding reclassification adjustments and tax effects relating to other comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYearDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |